Survanta Injection
Strength : 25mg
Ingredient : Beractant(25mg)
Company Name : Abbvie
Packing : 1 Vial
Uses : Survanta Injection, also known as Beractant, is a lung surfactant used primarily to prevent and treat respiratory distress syndrome (RDS) in premature infants. The injection helps replace the natural surfactant in the lungs, which is essential for proper lung function and breathing in newborns. Key Details: Indication: Used to treat and prevent RDS in premature infants. Administration: Administered intratracheally (directly into the windpipe) by a healthcare professional. Dosage: The dosage depends on the infant\'s weight and the severity of the condition.
Side Effects : Survanta (beractant) is used to treat or prevent respiratory distress syndrome (RDS) in premature infants. While it can be life-saving, it also has potential side effects. Here are some common and serious side effects: Common Side Effects: Bradycardia: Slowed heart rate. Hypotension: Low blood pressure. Apnea: Temporary cessation of breathing. Cyanosis: Bluish discoloration of the skin due to lack of oxygen. Pneumothorax: Collapsed lung. Serious Side Effects: Pulmonary Hemorrhage: Bleeding in the lungs. Infection: Increased risk of infections. Airway Obstruction: Blockage of the airways due to mucus or fluid buildup. Other Potential Side Effects: Sepsis: Severe infection that spreads through the bloodstream. Intracranial Hemorrhage: Bleeding in the brain. Patent Ductus Arteriosus: A heart condition where a blood vessel fails to close normally in newborns. Monitoring and Management: Frequent Monitoring: Close monitoring of vital signs (heart rate, blood pressure, oxygen levels) during and after administration. Supportive Care: Ventilatory support and other interventions may be necessary to manage side effects.
Survanta is generally administered in a hospital setting under the supervision of experienced healthcare professionals. The benefits of using Survanta typically outweigh the risks, especially in premature infants with RDS.